![Anders Gersel Pedersen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Anders Gersel Pedersen
Net worth: 3 M $ as of 31/12/2025
Profile
Anders Gersel Pedersen is currently Chief Executive Officer at Gerselconsult ApS, Deputy Chairman at Bavarian Nordic GmbH, Chairman at Fonden Lundbeck International Neuroscience Foundation, Chairman at Aelis Farma SA since 2020, Non-Independent Director at Genmab A since 2003, Director at Lundbeck Cognitive Therapeutics A, Director at Bond 2 Development 2 Gp Ltd., Member at American Society of Clinical Oncology, Inc., Member at European Society for Medical Oncology since 2010, Member at International Association for the Study of Lung Cancer, Member at Danish Society of Medical Oncology, Member at Danish Society of Internal Medicine, and Member-Supervisory Board at Avillion LLP since 2019.
Former roles include Deputy Chairman at Bavarian Nordic A from 2014 to 2025, Executive Director at Eli Lilly & Co., Director at Topotarget A, Independent Director at ALK-Abello A from 2005 to 2018, Director at Chr.
Hansen A, Director at TopoTarget UK Ltd., Independent Director at Hansa Biopharma AB from 2018 to 2025, Director at Bond Avillion 2 Development LP, and Executive Vice President-Research & Development at H.
Lundbeck A from 2011 to 2018.
Education includes undergraduate studies at Copenhagen Business School and a doctorate from the University of Copenhagen.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GENMAB A/S 0.01% | 12/02/2025 | 7,519 ( 0.01% ) | 2 M $ | 31/12/2025 |
BAVARIAN NORDIC A/S 0.02% | 31/12/2024 | 18,967 ( 0.02% ) | 569 952 $ | 31/12/2025 |
| 31/12/2024 | 2,500 ( 0% ) | 9 342 $ | 31/12/2025 |
Anders Gersel Pedersen active positions
| Companies | Position | Start |
|---|---|---|
| GENMAB A/S | Director/Board Member | 01/11/2003 |
| AELIS FARMA | Chairman | 01/01/2020 |
Bond 2 Development 2 Gp Ltd. | Director/Board Member | - |
Avillion LLP
 Avillion LLP Engages in clinical development of therapeutics | Director/Board Member | 05/09/2019 |
Bavarian Nordic GmbH
 Bavarian Nordic GmbH BiotechnologyHealth Technology Engages in research and development in biotechnology for cancer and infectious diseases | Director/Board Member | 01/01/2014 |
Lundbeck Cognitive Therapeutics A/S | Director/Board Member | - |
Fonden Lundbeck International Neuroscience Foundation
 Fonden Lundbeck International Neuroscience Foundation Functions as a foundation or endowment | Chairman | - |
Danish Society of Internal Medicine | Corporate Officer/Principal | - |
Danish Society of Medical Oncology | Corporate Officer/Principal | - |
| ░░░░░░░░░░░░░ ░░░░░░░░░░░ ░░░ ░░░ ░░░░░ ░░ ░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Former positions of Anders Gersel Pedersen
| Companies | Position | End |
|---|---|---|
| ░░░░░ ░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░ ░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Anders Gersel Pedersen
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 24 |
|---|---|
Eli Lilly & Co.
 Eli Lilly & Co. Manufactures, wholesales and markets pharmaceutical products | |
H. Lundbeck A/S
 H. Lundbeck A/S Pharmaceuticals: MajorHealth Technology Engages in the research, development, production and sale of pharmaceuticals for the treatment of brain diseases | Health Technology |
Genmab A/S
 Genmab A/S Pharmaceuticals: MajorHealth Technology Develops differentiated antibody therapeutics for treatment of cancer | Health Technology |
Bavarian Nordic A/S
 Bavarian Nordic A/S Pharmaceuticals: MajorHealth Technology Develops and produces novel vaccines for the treatment and prevention of life threatening diseases | Health Technology |
Topotarget A/S
 Topotarget A/S Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceuticals | Health Technology |
ALK-Abello A/S
 ALK-Abello A/S BiotechnologyHealth Technology Manufactures and produces pharmaceuticals for specific allergy vaccination, allergic symptoms & asthma | Health Technology |
Chr. Hansen A/S
 Chr. Hansen A/S Pharmaceuticals: OtherHealth Technology Manufactures natural food ingredient solutions | Health Technology |
Copenhagen Business School
 Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TopoTarget UK Ltd.
 TopoTarget UK Ltd. Drugstore ChainsRetail Trade Develops anti-cancer drugs | Retail Trade |
University of Copenhagen
 University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services Provides cancer treatment services | Health Services |
Hansa Biopharma AB
 Hansa Biopharma AB Pharmaceuticals: MajorHealth Technology Operates as a biotechnology research and development company | Health Technology |
European Society for Medical Oncology
 European Society for Medical Oncology Medical/Nursing ServicesHealth Services Operates as a medical oncology society | Health Services |
International Association for the Study of Lung Cancer
 International Association for the Study of Lung Cancer Miscellaneous Commercial ServicesCommercial Services The International Association for the Study of Lung Cancer (IASLC) is a global organization dedicated to the research and study of lung cancer. The company is based in Aurora, CO. With a focus on advancing the understanding and treatment of lung cancer, the IASLC brings together researchers, healthcare professionals, and advocates from around the world. Through collaboration and education, the organization aims to improve patient outcomes and reduce the global burden of lung cancer. | Commercial Services |
Bavarian Nordic GmbH
Bavarian Nordic GmbH BiotechnologyHealth Technology Engages in research and development in biotechnology for cancer and infectious diseases | Health Technology |
Lundbeck Cognitive Therapeutics A/S | |
Danish Society of Medical Oncology | |
Danish Society of Internal Medicine | |
Fonden Lundbeck International Neuroscience Foundation
Fonden Lundbeck International Neuroscience Foundation Functions as a foundation or endowment | |
Avillion LLP
Avillion LLP Engages in clinical development of therapeutics | |
Aelis Farma SA
 Aelis Farma SA Operates as a biotechnology company which develops drugs for brain diseases | |
Bond 2 Development 2 Gp Ltd. | |
Bond Avillion 2 Development LP | |
Gerselconsult ApS |
- Stock Market
- Insiders
- Anders Gersel Pedersen
